A Business at a Glance
0 of 1 daily views used (1 remaining). Sign up free for +5 more daily views (6 total), or try AAPL for a full preview.
SANGAMO THERAPEUTICS, INC
SGMO
$21M
Mkt Cap
SANGAMO THERAPEUTICS, INC (SGMO) has a 5-year average return on invested capital (ROIC) of -116.1%. This is below average and may indicate limited pricing power.
SANGAMO THERAPEUTICS, INC (SGMO) has a market capitalization of $123M. It is classified as a small-cap stock.
SANGAMO THERAPEUTICS, INC (SGMO) does not currently pay a regular dividend.
SANGAMO THERAPEUTICS, INC (SGMO) operates in the Biological Products, (No Diagnostic Substances) industry, within the Healthcare sector.
SANGAMO THERAPEUTICS, INC (SGMO) generated $-97 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
SANGAMO THERAPEUTICS, INC (SGMO) reported earnings per share (EPS) of $-0.44 in its most recent fiscal year.
The Ledger Terminal provides 17 years of financial data for SANGAMO THERAPEUTICS, INC (SGMO), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
ITEM 1 – BUSINESS We are a genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases. We believe our zinc finger epigenetic regulators are ideally suited to potentially address devastating neurology disorders and our capsid engineering platform has demonstrated the ability to expand delivery beyond currently available intrathecal delivery capsids, including in the central nervous system, or CNS, in preclinical studies. Our Core Neurology Programs Our neurology development is focused on two innovative areas: (i) development of epigenetic regulation therapies to treat serious neurological diseases and (ii) development of novel engineered adeno-associated virus, or AAV, capsids to deliver our therapies to the intended neurological targets.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 0 | - | 58M | 176M | 111M | 111M |
| Net Income | -123M | -123M | -98M | -258M | -192M | -178M |
| EPS | $-0.44 | $-0.44 | $-0.49 | $-1.48 | $-1.25 | $-1.23 |
| Free Cash Flow | -97M | -97M | -67M | -246M | -244M | -257M |
| ROIC | -160.3% | -160.3% | -185.4% | -136.5% | -57.4% | -40.8% |
| Gross Margin | - | 0.0% | - | - | - | - |
| Debt/Equity | 0.00 | -1.88 | 1.34 | 0.46 | 0.15 | 0.13 |
| Dividends/Share | $0.00 | $0.00 | - | - | - | - |
| Operating Income | -121M | -121M | -104M | -274M | -201M | -183M |
| Operating Margin | 0.0% | - | -179.9% | -155.5% | -180.8% | -165.6% |
| ROE | 0.0% | - | -185.4% | -136.5% | -57.4% | -40.8% |
| Shares Outstanding | 279M | 279M | 200M | 174M | 154M | 145M |
| Metric | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||||
| Revenue | 46M | 40M | N/A | 37M | 84M | 102M | 118M | 111M | 111M | 176M | 58M | N/A | 0 |
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% | N/A |
| R&D | 57M | 67M | 66M | 66M | 115M | 146M | 181M | 231M | 250M | 234M | 112M | 113M | 113M |
| SG&A | 16M | 19M | 26M | 27M | 47M | 62M | 67M | 63M | 63M | 61M | 45M | 35M | 35M |
| EBIT | -27M | -47M | -73M | -56M | -77M | -105M | -130M | -183M | -201M | -274M | -104M | -121M | -121M |
| Op. Margin | -58.4% | -118.5% | N/A | -154.1% | -91.4% | -102.7% | -109.6% | -165.6% | -180.8% | -155.5% | -179.9% | N/A | 0.0% |
| Net Income | -26M | -41M | -72M | -55M | -68M | -95M | -121M | -178M | -192M | -258M | -98M | -123M | -123M |
| Net Margin | -57.6% | -102.9% | N/A | -149.2% | -80.9% | -92.9% | -102.4% | -161.1% | -172.8% | -146.3% | -169.4% | N/A | 0.0% |
| Non-Recurring | 100K | 0 | 0 | -12K | 0 | -68K | -222K | 52K | 0 | 54M | 1.4M | 14M | 14M |
| Returns on Capital | |||||||||||||
| ROIC | -16.1% | -20.4% | -43.6% | -33.7% | -24.7% | -23.8% | -26.0% | -40.8% | -57.4% | -136.5% | -185.4% | -160.3% | -160.3% |
| ROE | -16.1% | -20.4% | -43.6% | -33.7% | -24.7% | -23.8% | -26.0% | -40.8% | -57.4% | -136.5% | -185.4% | N/A | 0.0% |
| ROA | -13.8% | -17.7% | -38.2% | -24.5% | -15.6% | -15.5% | -15.4% | -21.5% | -29.9% | -70.8% | -73.4% | -152.4% | -205.8% |
| Cash Flow | |||||||||||||
| Op. Cash Flow | -5.7M | -34M | -66M | 11M | 37M | -144M | 170M | -233M | -224M | -225M | -67M | -97M | -97M |
| Free Cash Flow | -6.3M | -36M | -67M | 7.4M | -6.5M | -165M | 155M | -257M | -244M | -246M | -67M | -97M | -97M |
| Owner Earnings | -15M | -46M | -82M | 592K | 20M | -168M | 138M | -276M | -267M | -267M | -85M | -110M | -110M |
| CapEx | 621K | 2.4M | 732K | 3.8M | 43M | 21M | 15M | 23M | 20M | 21M | 267K | 102K | 102K |
| Maint. CapEx | 549K | 988K | 997K | 1.5M | 2.4M | 3.9M | 5.7M | 9.4M | 12M | 15M | 5.1M | 4.0M | 4.0M |
| Growth CapEx | 72K | 1.4M | 0 | 2.3M | 41M | 17M | 9.0M | 14M | 8.1M | 6.1M | 0 | 0 | 0 |
| D&A | 549K | 988K | 997K | 1.5M | 2.4M | 3.9M | 5.7M | 9.4M | 12M | 15M | 5.1M | 4.0M | 4.0M |
| CapEx/OCF | N/A | N/A | N/A | 33.6% | 117.8% | N/A | 8.7% | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Capital Allocation | |||||||||||||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Buyback Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% | 0.0% |
| Stock-Based Comp | 9.2M | 12M | 15M | 9.1M | 15M | 19M | 26M | 33M | 32M | 27M | 12M | 9.1M | 9.1M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Balance Sheet | |||||||||||||
| Net Debt | N/A | N/A | N/A | N/A | N/A | -340M | -650M | -417M | -365M | -88M | -11M | 5.8M | 5.8M |
| Cash & Equiv. | 6.0M | 69M | 22M | 50M | 140M | 80M | 131M | 179M | 100M | 45M | 42M | 21M | 21M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 27M |
| Debt/Equity | 0.18 | 0.13 | 0.16 | 0.53 | 0.61 | 0.10 | 0.08 | 0.13 | 0.15 | 0.46 | 1.34 | -1.88 | 0.00 |
| Interest Coverage | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.0 | 0.0 |
| Equity | 207M | 192M | 136M | 188M | 367M | 433M | 498M | 375M | 295M | 83M | 23M | -14M | -14M |
| Total Assets | 243M | 217M | 158M | 287M | 590M | 638M | 939M | 722M | 563M | 165M | 102M | 60M | 60M |
| Total Liabilities | 37M | 25M | 22M | 99M | 223M | 205M | 441M | 347M | 268M | 82M | 79M | 74M | 74M |
| Intangibles | 1.9M | 0 | N/A | 0 | 54M | 53M | 58M | 54M | 51M | 0 | 0 | N/A | N/A |
| Retained Earnings | -329M | -369M | -441M | -495M | -563M | -657M | -778M | -956M | -1.1B | -1.4B | -1.5B | -1.6B | -1.6B |
| Working Capital | 170M | 192M | 136M | 204M | 332M | 336M | 516M | 271M | 189M | 47M | 5.9M | -6.6M | -6.6M |
| Current Assets | 191M | 213M | 150M | 248M | 411M | 405M | 660M | 399M | 300M | 94M | 52M | 36M | 36M |
| Current Liabilities | 21M | 20M | 13M | 45M | 79M | 70M | 144M | 128M | 112M | 48M | 46M | 42M | 42M |
| Per Share Data | |||||||||||||
| EPS | -0.39 | -0.58 | -1.02 | -0.70 | -0.70 | -0.85 | -0.90 | -1.23 | -1.25 | -1.48 | -0.49 | -0.44 | -0.44 |
| Owner EPS | -0.23 | -0.66 | -1.17 | 0.01 | 0.20 | -1.50 | 1.03 | -1.90 | -1.74 | -1.53 | -0.42 | -0.39 | -0.39 |
| Book Value | 3.05 | 2.74 | 1.94 | 2.41 | 3.75 | 3.86 | 3.71 | 2.59 | 1.92 | 0.48 | 0.11 | -0.05 | -0.05 |
| Cash Flow/Share | -0.08 | -0.48 | -0.94 | 0.14 | 0.37 | -1.29 | 1.26 | -1.61 | -1.45 | -1.29 | -0.34 | -0.35 | -0.43 |
| Dividends/Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.00 | 0.00 |
| Shares Out. | 67.7M | 70.2M | 70.3M | 78.0M | 97.6M | 112.0M | 134.4M | 144.9M | 153.8M | 174.2M | 199.9M | 279.4M | 279.4M |
| Valuation | |||||||||||||
| P/E Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -1.0 |
| P/FCF | N/A | N/A | N/A | 178.9 | N/A | N/A | 15.6 | N/A | N/A | N/A | N/A | N/A | N/A |
| EV/EBIT | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price/Book | 4.8 | 3.4 | 1.5 | 7.1 | 2.9 | 2.2 | 4.9 | 3.1 | 1.4 | 1.3 | 22.5 | N/A | N/A |
| Price/Sales | 21.6 | 19.7 | N/A | 19.2 | 18.9 | 11.3 | 11.1 | 14.3 | 6.7 | 1.4 | 3.3 | N/A | N/A |
| FCF Yield | -0.6% | -5.6% | -32.7% | 0.6% | -0.6% | -17.6% | 6.4% | -21.8% | -57.0% | -235.3% | -13.2% | N/A | -79.2% |
| Market Cap | 991M | 645M | 204M | 1.3B | 1.1B | 936M | 2.4B | 1.2B | 428M | 105M | 512M | 0 | 123M |
| Avg. Price | 14.65 | 11.09 | 5.34 | 9.01 | 16.39 | 10.34 | 9.74 | 10.94 | 4.88 | 1.46 | 0.95 | 0.00 | 0.44 |
| Year-End Price | 14.63 | 9.19 | 2.90 | 17.05 | 10.86 | 8.36 | 18.04 | 8.11 | 2.78 | 0.60 | 2.56 | 0.00 | 0.44 |
SANGAMO THERAPEUTICS, INC passes 2 of 9 quality checks, indicating weak fundamentals.
At current prices, the estimated annualized return to fair value is +74.7%.
SANGAMO THERAPEUTICS, INC (SGMO) has a book value per share of $-0.05, based on its most recent annual SEC filing.